Capricor Therapeutics (CAPR) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Capricor Therapeutics (CAPR) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
723,416.35 Bn |
723,416.32 Bn |
- |
- |
| 2 |
Belite Bio |
57,340.00 Bn |
57,340.00 Bn |
- |
84.25% |
| 3 |
Quantum Biopharma |
19,125.08 Bn |
19,125.08 Bn |
- |
-10.84% |
| 4 |
Legend Biotech |
3,262.00 Bn |
3,261.71 Bn |
242.10 Mn |
26.38% |
| 5 |
Akari Therapeutics |
1,789.67 Bn |
1,789.67 Bn |
- |
-46.86% |
| 6 |
Evaxion A |
1,480.39 Bn |
1,480.37 Bn |
- |
34.98% |
| 7 |
Psyence Biomedical |
241.78 Bn |
241.78 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.54 Bn |
106.29 Bn |
2.59 Bn |
13.80% |
| 9 |
Abivax |
94.26 Bn |
94.26 Bn |
- |
- |
| 10 |
Capricor Therapeutics |
1.53 Bn |
1.26 Bn |
- |
-63.48% |
| Date | Value |
|---|
| Mar 31, 2026 |
-63.48% |
| Dec 31, 2025 |
-52.26% |
| Sep 30, 2025 |
-56.82% |
| Jun 30, 2025 |
-52.57% |
| Mar 31, 2025 |
-46.12% |
| Dec 31, 2024 |
84.22% |
| Sep 30, 2024 |
-42.95% |
| Jun 30, 2024 |
-29.49% |
| Mar 31, 2024 |
-23.88% |
| Dec 31, 2023 |
41.67% |
| Sep 30, 2023 |
-17.76% |
| Jun 30, 2023 |
-28.35% |
| Mar 31, 2023 |
-55.03% |
| Dec 31, 2022 |
-73.59% |
| Sep 30, 2022 |
-58.28% |
| Jun 30, 2022 |
-52.86% |
| Mar 31, 2022 |
-45.86% |
| Dec 31, 2021 |
-24.98% |
| Sep 30, 2021 |
-1.30% |
| Jun 30, 2021 |
-7.11% |
